Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 11, Issue 10 pp 3348—3361
circFADS2 protects LPS-treated chondrocytes from apoptosis acting as an interceptor of miR-498/mTOR cross-talking
Figure 8. miR-498 targets the mTOR. (A) Bioinformatic analysis showing that miR-498 has a binding site in the 3′-UTR of mTOR. (B) DLRA was performed following co-transfection of chondrocytes with a luciferase reporter containing either a WT (wild-type) or MU (mutant) mTOR and a miR-498 mimic. (C) qPCR analysis showing the significantly increased mTOR expression levels in RA patients. (D, E) Chondrocytes were transfected with si-circFADS2 or miR-498 mimic and then treated with LPS. qPCR and WB analysis were carried out to detect mTOR levels in each group. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control cells; #P < 0.05, ###P < 0.001 vs. LPS group.